Key Takeaways
- • Wittington Investments, the holding company of Canada's Weston family, acquired Boots for $8.9 billion (£6.74bn), marking a decisive exit by long-term owner Stefano Pessina and financial backer Sycamore Partners after years of failed sale attempts.
- • The deal encompasses Boots' 1,800 UK and Irish retail stores, opticians operations, the No7 beauty brand, and a Thailand franchise, along with 50,000 employees, making it one of Britain's largest retail acquisitions in recent years.
- • Fairfax, a major Canadian investment firm, co-backed the transaction alongside Wittington, providing validation and capital support for the cross-border acquisition of the Nottingham-headquartered pharmacy and beauty chain.
- • The transaction is expected to close in Q1 2027, subject to regulatory approval, after Walgreens' failed 2022 sale process and a botched 2024 IPO attempt saw valuations decline from £10bn to the current $8.9bn deal price.
- • Galen Weston, chair of Wittington and controller of Canada's Loblaws grocery and Drugmart pharmacy chains, is positioned to become chair of Boots, signaling plans for long-term ownership and capital investment in the struggling retailer.
Summary
The Weston family of Canada has acquired Boots, the iconic UK pharmacy and beauty retailer, for $8.9 billion through Wittington Investments, their holding company. The transaction represents a major reshuffling of ownership at the Nottingham-headquartered chain, which operates 1,800 stores across the UK and Ireland and employs 50,000 people. The deal includes Boots' UK and Irish retail operations, opticians chain, the No7 beauty brand, and a franchise operation in Thailand. Fairfax, a prominent Canadian investment firm that owns The Sporting Life Group and Sleep Country Canada, is co-backing the acquisition alongside Wittington.
The acquisition marks a decisive exit for Stefano Pessina, who has maintained a controlling stake in Boots for years, and for Sycamore Partners, the financial firm that had backed him more recently. The transaction closes a protracted sales process that began in 2022 when Walgreens initially attempted to divest Boots with an asking price of up to £10 billion but withdrew amid buyer financing challenges and weak market sentiment. Potential acquirers during that period included Mukesh Ambani's Reliance Industries, Apollo Global Management, and TDR Capital. A separate attempt to float Boots on public markets at a valuation of approximately £7 billion was abandoned in 2024, reflecting persistent challenges in finding buyers and diminished valuations.
Galen Weston, chair of Wittington Investments and head of the Loblaws and Drugmart operations in Canada, is expected to become chair of Boots. In a statement, Weston emphasized the Weston family's commitment to stable, long-term ownership, additional capital investment, and renewed operational focus to serve customers across the UK and Ireland. The deal is subject to regulatory approval and is anticipated to close in the first quarter of 2027, signaling that the Weston family views Boots as a strategic addition to its North American and international retail footprint in pharmacy and consumer health.
The acquisition marks a decisive exit for Stefano Pessina, who has maintained a controlling stake in Boots for years, and for Sycamore Partners, the financial firm that had backed him more recently. The transaction closes a protracted sales process that began in 2022 when Walgreens initially attempted to divest Boots with an asking price of up to £10 billion but withdrew amid buyer financing challenges and weak market sentiment. Potential acquirers during that period included Mukesh Ambani's Reliance Industries, Apollo Global Management, and TDR Capital. A separate attempt to float Boots on public markets at a valuation of approximately £7 billion was abandoned in 2024, reflecting persistent challenges in finding buyers and diminished valuations.
Galen Weston, chair of Wittington Investments and head of the Loblaws and Drugmart operations in Canada, is expected to become chair of Boots. In a statement, Weston emphasized the Weston family's commitment to stable, long-term ownership, additional capital investment, and renewed operational focus to serve customers across the UK and Ireland. The deal is subject to regulatory approval and is anticipated to close in the first quarter of 2027, signaling that the Weston family views Boots as a strategic addition to its North American and international retail footprint in pharmacy and consumer health.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.